Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

Status: Open to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT04711824

Study Contact: studies@hoosiercancer.org; (317) 921-2050.